Different phenotype relapse of myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement with long remission-Reference-Cited by-同舟云学术

Different phenotype relapse of myeloid/lymphoid neoplasms with FGFR1 rearrangement with long remission

Published:2023-10-13 Issue:1 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Sugiyama Masanaka¹,Arakawa Ayumu¹²,Kogure Yasunori³,Shirakawa Nami¹,Watanabe Mizuki⁴,Ito Yuta³,Tanimura Kazuki¹,Tao Kayoko¹,Nakajima Miho¹,Watanabe Yuko¹,Miyagi‐Maeshima Akiko⁵,Fukuhara Suguru⁶,Kataoka Keisuke³⁷,Izutsu Koji⁶,Fukuda Takahiro⁴,Ogawa Chitose¹²

Affiliation:

1. Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan

2. Rare Cancer Center National Cancer Center Hospital Tokyo Japan

3. Division of Molecular Oncology National Cancer Center Research Institute Tokyo Japan

4. Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan

5. Department of Diagnostic Pathology National Cancer Center Hospital Tokyo Japan

6. Department of Hematology National Cancer Center Hospital Tokyo Japan

7. Division of Hematology Department of Medicine Keio University School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30721

Reference16 articles.

1. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement

2. Myeloid neoplasms with eosinophilia

3. Intensive ALL‐type therapy without local radiotherapy provides a 90% event‐free survival for children with T‐cell lymphoblastic lymphoma: a BFM group report;Reiter A;Blood,2000

4. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies

5. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial